The research and teaching performed by PPP Initiative Ltd. is aimed at addressing complex public policy challenges in a variety of countries. We primarily work with developing and emerging economies across various stakeholders such as governments, multinational corporations, multilaterals, non-profits, and foundations.
This 2018 white paper reflects on the lessons learned and paths forward from PPPI’s Case Development Program and series of Healthcare PPP Forums in China and Singapore. It touches on issues including the necessity of case-based curricula for teaching PPP and focuses on three key recommendations around the convergence of NCDs and eldercare, a flexible PPP model, and building capacity for PPP.
This 2015 study was researched and published during PPP Initiative’s affiliation with Johns Hopkins University’s School of Advanced International Studies. Over the course of 18 months and using a data-driven approach, a research team lead by Prof. Trager and principal researcher Molly Guan identified China and India’s varying constraints and abilities to leverage PPP, especially in healthcare, finding that the two countries faced many similar challenges and three key gaps: execution, financing and innovation.
The Eli Lilly Foundation provided funding for the research and preparation of the Mapping Study.Download in English Download in Chinese
Amgen, Inc. supported an independent research project by PPP Initiative Ltd. to create a set of case studies related to healthcare PPPs relevant to Asia. The case studies aim to be the definitive model for capacity building in healthcare PPPs in China and beyond. The Case Study Program included five forums: two in Beijing; two in Singapore and one in Washington D.C.
A case study about China’s recovery from a catastrophic earthquake in 2008 (58,000 people were injured or dead in two minutes).
A case study about a city medical park formed as a PPP in Shanghai.
A case study about the transformation of the Boston Archdiocese Hospital System as a result of a $900 million private equity transaction and the recruitment of a Harvard Medical School cardiovascular surgeon as CEO.